Menarini Diagnostics UK has announced it has received Coronavirus Test Device Approval (CTDA) for the Coyote FlashDetect SARS-CoV-2, Influenza A, Influenza B, Respiratory Syncytial Virus assay.
The NHS and healthcare providers continue to face intense winter pressures, this multiplex assay provides rapid, accurate and reliable results to optimise patient management, streamline bed allocation and ensure robust staff protection.
The Coyote Flash10 is a cartridge based rapid molecular PCR system. Its random-access design, expanding assay menu and cost-effective all-in-one cartridges make this the ideal solution for health care providers requiring fast accurate molecular diagnostics without compromising workflow efficiency. Results from a single patient sample are ready within 35 minutes.
Dr Jonathan Coffey, Managing Director at A Menarini Diagnostics UK, commented: “We are delighted to launch this best in class and cutting-edge system within the UK healthcare sector. Providing clinicians with fast, accurate data is crucial, and this innovation will directly support them in delivering exceptional patient outcomes."